<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112567</url>
  </required_header>
  <id_info>
    <org_study_id>1629.00</org_study_id>
    <secondary_id>FHCRC-1629.00</secondary_id>
    <secondary_id>CDR0000430650</secondary_id>
    <nct_id>NCT00112567</nct_id>
  </id_info>
  <brief_title>Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer</brief_title>
  <official_title>A Phase I/II Study of Total Body Irradiation, Thiotepa, and Fludarabine as Conditioning for Haploidentical CD34+ Purified Peripheral Blood Stem Cell Transplants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemotherapy, such as fludarabine and thiotepa, and radiation therapy may destroy&#xD;
      cancerous blood-forming cells (stem cells) in the blood and bone marrow. Giving healthy stem&#xD;
      cells from a donor whose blood closely resembles the patient's blood will help the patient's&#xD;
      bone marrow make new stem cells that become red blood cells, white blood cells, and&#xD;
      platelets.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects of total-body irradiation,&#xD;
      fludarabine, and thiotepa and to see how well they work in treating young patients who are&#xD;
      undergoing a donor stem cell transplant for hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of a conditioning regimen without anti-thymocyte globulin&#xD;
           comprising total body irradiation, thiotepa, and fludarabine followed by&#xD;
           CD34-positive-selected haploidentical allogeneic peripheral blood stem cell&#xD;
           transplantation in young patients with life-threatening hematologic malignancies.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the risk for severe graft-vs-host disease in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the kinetics of immune reconstitution in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the risk for life-threatening infections in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Conditioning regimen: Patients 7 years of age and under undergo total body irradiation&#xD;
           twice daily on days -9 to -7. Patients over 7 years of age undergo total body&#xD;
           irradiation once on day -7. All patients receive fludarabine IV once daily on days -6 to&#xD;
           -2 and thiotepa IV over 2 hours twice on day -5.&#xD;
&#xD;
        -  CD34-positive (CD34+)-selected haploidentical allogeneic peripheral blood stem cell&#xD;
           transplantation (PBSCT): Patients undergo CD34+-selected allogeneic PBSCT on days 0 and&#xD;
           2.&#xD;
&#xD;
      Patients with acute lymphoblastic leukemia or CNS disease also receive methotrexate&#xD;
      intrathecally twice before transplantation and 4 times after day 35 post-transplantation.&#xD;
      Male patients with lymphoid malignancies undergo additional radiotherapy to the testes.&#xD;
&#xD;
      After completion of study treatment, patients are followed for at least 100 days, at 1 year,&#xD;
      and then periodically thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients (10 patients ≤ 7 years of age and 10 patients &gt; 7&#xD;
      years of age) will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date>July 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk of severe graft-versus-host disease</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetics of immune reconstitution</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of life-threatening infections</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of a life-threatening hematologic malignancy, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Acute leukemia advanced beyond first remission&#xD;
&#xD;
               -  Acute leukemia in first remission* with very high-risk prognostic features,&#xD;
                  including any of the following:&#xD;
&#xD;
                    -  Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL)&#xD;
&#xD;
                    -  ALL or acute myeloid leukemia (AML) with 11q23 chromosomal abnormality&#xD;
&#xD;
                    -  Hypodiploid ALL&#xD;
&#xD;
                    -  Failed to achieve first remission within 1 month after induction therapy&#xD;
&#xD;
                    -  Secondary AML&#xD;
&#xD;
               -  Myelodysplastic syndromes with International Prognostic Index score &gt; 1&#xD;
&#xD;
               -  Chronic myelogenous leukemia in accelerated or blast phase NOTE: *Must be&#xD;
                  approved by PCC&#xD;
&#xD;
          -  Haploidentical family donor available&#xD;
&#xD;
               -  No suitable HLA-matched related or unrelated donor available&#xD;
&#xD;
               -  No related donor mismatched for a single HLA-A, -B, -C, -DRB1, or -DQB1 antigen&#xD;
                  available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Under 21&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGPT and SGOT &lt; 2 times upper limit of normal (ULN)*&#xD;
&#xD;
          -  Bilirubin &lt; 2 times ULN* NOTE: *Unless due to malignancy&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction ≥ 45%&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO ≥ 60% of predicted&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No second bone marrow transplantation, after a first regimen containing total body&#xD;
             irradiation&#xD;
&#xD;
          -  No concurrent growth factors until day 21 post-transplantation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann E. Woolfrey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>June 2, 2005</study_first_submitted>
  <study_first_submitted_qc>June 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2005</study_first_posted>
  <last_update_submitted>September 17, 2010</last_update_submitted>
  <last_update_submitted_qc>September 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2010</last_update_posted>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

